Pfizer chairman and CEO Albert Bourla: Our oncology drugs will be blockbuster ones
2 months ago
19
"Seagen acquisition and oncology. It is what it is our new Covid. So we did what we did with Covid. We are very proud, we saved the world, but it is behind us now. We want to do once more and I think oncology is our best chance to do it. But of course with many other therapeutic areas...I think will be blockbuster drugs. And more importantly, they will be blockbuster drugs because they will have significant impact on cancer patients...But what excites me most is not how the current projects are doing. Of course I'm very happy because they are helping people. But when I reviewed the pipeline which is coming out with ADC technology, I really think we will move the needle into overall survival of cancer."
Loading 1 comment...
-
1:24
RedpillUSAPatriots
2 months agoPfizer chairman and CEO Albert Bourla: Seagen acquisition and oncology
4.33K9 -
11:30
Knowjust1c3
3 months agoPfizer Is Now In The Cancer Fighting Business
1772 -
1:24
AC News
2 months agoUSA: Pfizer CEO Albert Bourla: "Seagen acquisition and oncology, it is what it is our new Covid!
311 -
2:53
AMERICAEXPOSED
1 year agoPfizer CEO Albert Bourla Announces Acquisition of Cancer Treatment Biotech Seagen For $43 Billion
210 -
21:30
jess93
2 months agoBig Pharma CEO PFIZER New Blockbuster Drugs Saving The World and His Prediction About Cancer Drug
611 -
2:38
RedpillUSAPatriots
1 year agoPfizer CEO Albert Bourla Announces Acquisition of Cancer Treatment Biotech Seagen For $43 Billion
2.2K13 -
2:38
alexlunaviewer
1 year agoPfizer CEO Albert Bourla Announces Acquisition of Cancer Treatment Biotech Seagen For $43 Billion
2511 -
2:38
jess93
5 months agoEmpire PFIZER Bought Seagen Cancer for $43 Billion CEO Bourla Ready to Cash Billions$: He Said 1 out 3 People Globally Will Have Cancer
96 -
1:24
VirtueNews
2 months agoPfizer chairman talks about how they will impact cancer patients
491 -
2:38
Truthseekers17
1 year agoPfizer CEO Albert Burla Announces $43 Billion Acquisition of Seagen Cancer Biotechnology
34